Details of the Drug
General Information of Drug (ID: DM3ZNF9)
Drug Name |
JNJ-1661010
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
681136-29-8; JNJ-1661010; JNJ 1661010; JNJ1661010; N-phenyl-4-(3-phenyl-1,2,4-thiadiazol-5-yl)piperazine-1-carboxamide; UNII-62521S57AU; 1-Piperazinecarboxamide, N-phenyl-4-(3-phenyl-1,2,4-thiadiazol-5-yl)-; N-PHENYL-4-(3-PHENYL-1,2,4-THIADIAZOL-5-YL)-1-PIPERAZINECARBOXAMIDE; CHEMBL460273; 62521S57AU; BHBOSTKQCZEAJM-UHFFFAOYSA-N; ACMC-20emff; AC1MDCTI; AC1Q5LMB; Oprea1_746619; MLS001111246; SCHEMBL1164398; GTPL5206; CTK1J2536; cid_2809273; DTXSID00384599; MolPort-001-806-365; HMS3651L15; HMS1662H10; HMS2801K13; BCP06935; EX-A2218
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 365.5 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 3.5 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 5 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References